We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Hologic (HOLX) Q1 Earnings
Read MoreHide Full Article
Wall Street analysts expect Hologic (HOLX - Free Report) to post quarterly earnings of $0.94 per share in its upcoming report, which indicates a year-over-year decline of 12.2%. Revenues are expected to be $983.25 million, down 8.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Hologic metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenue- GYN Surgical' to come in at $150.00 million. The estimate indicates a year-over-year change of -2.7%.
The average prediction of analysts places 'Revenues- Diagnostics- Molecular Diagnostics' at $323.41 million. The estimate indicates a year-over-year change of -23.9%.
The consensus estimate for 'Revenues- Diagnostics- Blood Screening' stands at $9.38 million. The estimate points to a change of +28.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Breast Health- Breast Imaging' should come in at $280.17 million. The estimate points to a change of +6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Total Diagnostics' will likely reach $447.49 million. The estimate indicates a change of -20% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Skeletal Health' will reach $26.97 million. The estimate indicates a year-over-year change of +1.4%.
Analysts predict that the 'Revenues- Diagnostics- Cytology & Perinatal' will reach $116.71 million. The estimate indicates a year-over-year change of -8%.
It is projected by analysts that the 'Revenue- Total Breast Health' will reach $352.90 million. The estimate suggests a change of +5.6% year over year.
Analysts' assessment points toward 'Revenues- Breast Health- Interventional Breast Solutions' reaching $72.73 million. The estimate suggests a change of +4.2% year over year.
The collective assessment of analysts points to an estimated 'Service and other revenue' of $178.29 million. The estimate indicates a year-over-year change of -5.1%.
Analysts forecast 'Product Sales' to reach $801.50 million. The estimate indicates a change of -9.6% from the prior-year quarter.
Shares of Hologic have experienced a change of +4.1% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), HOLX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Hologic (HOLX) Q1 Earnings
Wall Street analysts expect Hologic (HOLX - Free Report) to post quarterly earnings of $0.94 per share in its upcoming report, which indicates a year-over-year decline of 12.2%. Revenues are expected to be $983.25 million, down 8.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Hologic metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenue- GYN Surgical' to come in at $150.00 million. The estimate indicates a year-over-year change of -2.7%.
The average prediction of analysts places 'Revenues- Diagnostics- Molecular Diagnostics' at $323.41 million. The estimate indicates a year-over-year change of -23.9%.
The consensus estimate for 'Revenues- Diagnostics- Blood Screening' stands at $9.38 million. The estimate points to a change of +28.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Breast Health- Breast Imaging' should come in at $280.17 million. The estimate points to a change of +6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Total Diagnostics' will likely reach $447.49 million. The estimate indicates a change of -20% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Skeletal Health' will reach $26.97 million. The estimate indicates a year-over-year change of +1.4%.
Analysts predict that the 'Revenues- Diagnostics- Cytology & Perinatal' will reach $116.71 million. The estimate indicates a year-over-year change of -8%.
It is projected by analysts that the 'Revenue- Total Breast Health' will reach $352.90 million. The estimate suggests a change of +5.6% year over year.
Analysts' assessment points toward 'Revenues- Breast Health- Interventional Breast Solutions' reaching $72.73 million. The estimate suggests a change of +4.2% year over year.
The collective assessment of analysts points to an estimated 'Service and other revenue' of $178.29 million. The estimate indicates a year-over-year change of -5.1%.
Analysts forecast 'Product Sales' to reach $801.50 million. The estimate indicates a change of -9.6% from the prior-year quarter.
View all Key Company Metrics for Hologic here>>>
Shares of Hologic have experienced a change of +4.1% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), HOLX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>